

Public Health Nutrition

<http://journals.cambridge.org/PHN>


Additional services for **Public Health Nutrition**:

Email alerts: [Click here](#)

Subscriptions: [Click here](#)

Commercial reprints: [Click here](#)

Terms of use : [Click here](#)



Efficacy and safety of a *Ginkgo biloba* extract

PL Le Bars and J Kastelan

Public Health Nutrition / Volume 3 / Supplement 4a / December 2000, pp 495 - 499
DOI: 10.1017/S1368980000000574, Published online: 02 January 2007

Link to this article: http://journals.cambridge.org/abstract_S1368980000000574

How to cite this article:

PL Le Bars and J Kastelan (2000). Efficacy and safety of a *Ginkgo biloba* extract. Public Health Nutrition, 3, pp 495-499
doi:10.1017/S1368980000000574

Request Permissions : [Click here](#)

Efficacy and safety of a *Ginkgo biloba* extract

PL Le Bars^{1,2,*} and J Kastelan^{2,3}

¹New York University Medical Center, New York, USA; ²Memory Centers of America, 225 East 64th Street, Suite C-102, 10021 New York, USA; ³HZI Research Center, Elmsford, NY, USA

Abstract

This review of the literature documents the efficacy of a standard extract of *Ginkgo biloba* (EGb) in managing signs and symptoms associated with memory disorders and dementia. Analysis of the discrepant findings reveals that study outcomes may vary with the type of population studied, the outcome measurements selected, and the dosing tested. Overall, the efficacy of EGb was more frequently reported in trials enrolling dementia patients than healthy volunteers. In contrast to narrow memory tests, broad cognitive assessments were more likely to detect the treatment effect. Although a dose–response relationship is not yet established, 240 mg day⁻¹ EGb seems to show a higher rate of treatment response than does 120 mg day⁻¹. Regarding safety, in all trials reviewed the adverse event profile of EGb was not different from that of the placebo.

Keywords

Ginkgo biloba

EGb 761

Memory

EEG

Alzheimer's Disease

Dementia

Randomized Controlled Trial

The last 20 years have produced a large body of evidence demonstrating the efficacy of *Ginkgo biloba* in the management of symptoms of a range of disorders affecting the nervous and vascular systems. However, the very same fields that demonstrated efficacy have simultaneously yielded contradictory results. While an underpowered study or a study applying an inadequate design could occasionally explain a negative outcome, many trials meeting standard criteria nevertheless led to inconsistent findings. An analysis of the discrepant results reveals at least three confounding factors: (1) the characteristics of the study population, (2) the type of outcome measurements, and (3) the ginkgo dosing tested in the trial.

Each of these factors could be a source of discrepancy among studies and may be an important element to be considered for ensuring success in the use of the herbal remedy. This review will summarize the results of studies testing the effects of a standardized extract of ginkgo on cognitive domains.

Extract of ginkgo and standardization

Standardization of herbal remedies in general and of ginkgo in particular is an essential factor to reduce variability in research programmes. Most of the studies reviewed below tested a standardized extract of *Ginkgo biloba*, EGb 761[®] (EGb), whose formulation and composition is identical to the product registered in Germany under the name Tebonine[®] forte (Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe). A standardized method is

used to prepare the concentrated extract exclusively from the dried leaves of the ginkgo tree and ensures stability in the ratio of the most active constituents, ginkgo-flavonoids (24%) and terpene-lactones (6%). The standardization also aims to reduce the concentration of ginkgolic acids (i.e. less than 5 ppm) that are considered allergenic. Seventy percent of the total constituents of the extract are systematically verified to ensure EGb's consistent quality, regardless of the origin of the raw material.

Memory and neuropsychological testing

Neuropsychological testing of memory and related cognitive processes provides a favourable domain in which to demonstrate the influence of two confounding factors on the efficacy of EGb: (1) the characteristics of the population studied and (2) the adequate selection of outcome measurements. In the EGb studies summarized in Tables 1 and 2, efficacy was systematically demonstrated when the population consisted of subjects cognitively impaired at baseline and rarely when it was a group of healthy volunteers^{1–7}. Furthermore, the assessments measuring accuracy and speed, mostly related to working memory, were more successful for observing the EGb effect than the assessments measuring long term storage and retrieval abilities (delayed recall and recognition). Warot reported a striking positive effect of EGb on a memory test that assessed the immediate recall of 20 pictures¹. However, this difference was not due to an improvement in performance of the EGb group (mean recall of 15.5 pictures at baseline vs. 15.6 pictures

Table 1 Memory and neuropsychological testing in healthy volunteers

Publication (dosing regimen)	Mental domain or test	Outcome measure results
Warot <i>et al.</i> ¹ (600 mg)	Critical flicker frequency, choice reaction time Sternberg number recognition (working memory), picture recognition Picture immediate recall	NS* NS NS change from baseline in EGb group; however, $P < 0.05$ vs. placebo NS
Subhan and Hindmarch ² (120, 240, 600 mg)	Critical flicker frequency, choice reaction time Sternberg number recognition (working memory)	NS Significant difference 600 mg vs. placebo for response time only

* NS = No statistically significant difference from placebo.

1 h after 600 mg EGb) but rather to a statistically significant decline in the performance of the placebo group (15.7 pictures at baseline vs. 13 at the 1 h session). The authors suggested that EGb may have a preventative rather than a memory enhancing effect. However, considering the healthy population enrolled in the study, the short duration of the trial and the lack of withdrawal phase, such preventative potential remains hypothetical.

The adequate dosage of EGb for achieving efficacy in these cognitive domains varied widely depending on the treatment regimen (single or chronic dosing). Overall, higher dosages (up to 600 mg day⁻¹) seemed to be generally required for achieving efficacy on memory when acute single dose treatment was employed. The dose factor, however, has not been systematically handled in the currently available trials and additional studies comparing multiple dosages and different regimens are needed.

Electrophysiology

Electrophysiology is another field of interest in which to assess the effect of EGb on cognitive disorder, particularly because of the sensitivity of the electroencephalogram (EEG) to changes of vigilance and its use as a bioassay to

assess the pharmacodynamic effects of CNS active agents. Theta/alpha ratio and profile of change in the beta, alpha, and theta bands have been considered the most adequate outcome measures for demonstrating the effects of the so-called 'nootropic' agents and 'cognitive activators'. These agents usually increase alpha and slow beta and/or theta band activity, resulting in an overall acceleration of the EEG background.

As shown in Table 3, EGb significantly affects the human EEG. In healthy volunteers, it has been shown that EGb induces an increase in the alpha and slow beta fractions of the EEG spectrum⁸⁻¹¹. In patient populations (Table 4), it appears more likely to reduce the occurrence of slow activities (theta), thus decreasing the theta/alpha ratio¹²⁻¹⁵. Conflicting trial findings are mostly due to different baseline characteristics, circadian fluctuation of outcome measures, or complex dose-response curves. An example of interference between baseline characteristics and outcome measure can be seen in the Kunkel study, which failed to show a significant increase of alpha activity in healthy volunteers receiving a dose of 160 mg day⁻¹ EGb for 3 days⁹. Two of the inclusion criteria were a high alpha ratio in the baseline EEG (70% of the background activity had to be in the alpha band) and a dominant alpha frequency between 9 and 11 Hz. These extremely selective

Table 2 Memory and neuropsychological testing in an elderly population with mild to moderate cognitive impairment

Publication (dosing regimen)	Mental domain or test	Outcome measure results
Allain <i>et al.</i> ³ (320, 600 mg)	Word/drawing immediate recall	NS
	Dual coding time (speed of data processing)	Significant shift toward normal time in the EGb groups
Grassel ⁴ (80 mg bid, 24 weeks)	Memory learning rate	NS
Hofferberth ⁵ (40 mg tid, 8 weeks)	Short term memory	Statistically significant difference from placebo at 24 weeks
	Complex reaction time	Statistically significant difference from placebo at 8 weeks
Israel <i>et al.</i> ⁶ (80 mg bid, 12 weeks)	Trail making (attention)	NS
	Learning rate and global memory	NS
	Attention and working memory	Statistically significant difference from placebo at 12 weeks
	Mental fluidity (speed of data processing)	Statistically significant difference from placebo at 12 weeks
Wesnes <i>et al.</i> ⁷ (40 mg tid, 12 weeks)	Benton/Word recall and recognition	NS
	Number matching, speed of processing and mental efficiency	Statistically significant difference from placebo at 8 and 12 weeks

Table 3 Electrophysiology in healthy volunteers

Publication (dosing regimen)	EEG changes	Outcome measure results
Itil <i>et al.</i> ⁸ (40, 120, 240 mg single dose)	Increase alpha	Statistical significance from placebo, all doses. Linear dose–response
Kunkel ⁹ (40, 80, 160 mg 3 days)	Increase beta activity, decrease theta	Statistical significance from placebo after 3 days 80 and 160 mg. No dose–response
Le Bars <i>et al.</i> ¹⁰ (80, 120, 240 mg single dose)	Increase alpha, decrease theta	Statistical significance from placebo 3 h after 120 or 240 mg (EEG and vigilance). Bimodal dose–response curve
Luhringer <i>et al.</i> ¹¹ (80, 160 mg single and 5 days)	Increase alpha after single dose, decrease theta, increase beta after 5 days	Statistical significance from placebo 80, 160 mg single dose and 5 days of chronic treatment

criteria resulted in the exclusion of 50% of the healthy population screened. Not surprisingly, with such a rigid pre-selected EEG background, EGb induced only minor changes in the alpha band (no change in the occipital areas) but significant changes in the other frequencies. The EGb group showed an expected increase in slow beta activity but a surprising decrease in theta activity, which reached statistical significance compared with placebo.

An example of multiple interference between selection of study population, baseline EEG, and outcome measurement is found in the Gessner study, which enrolled a heterogeneous group of elderly volunteers suffering from non-specific cognitive decline¹⁴. Results based on mean comparisons of six EEG bands did not show significant changes after chronic dosing of 120 mg day⁻¹ EGb during a 12-week period. However, when a more homogeneous subgroup of patients with slow alpha background was selected (most impaired cases), EGb induced a significant decrease of the theta/alpha ratio and an increase of alpha dominant frequency, particularly during the resting EEG sessions. The authors attributed these changes to an improvement of vigilance. By selecting a subgroup of participants with the slowest alpha background, Gessner increased the probability of inclusion of subjects with more objective impairment and increased the magnitude of the treatment effect compared with placebo.

Discrepant results may also reflect a complex pharmacodynamic dose–response relationship. Kunkel failed to find a dose–response relationship for doses of 40, 80 and 160 mg day⁻¹ after 3 days of chronic administration⁹. Itil, however, reported a statistically significant increase of alpha activity compared with placebo with a linear dose–response relationship in a pilot study with multiple single doses of EGb (40–240 mg)⁸. No statistically significant

differences in the alpha band were observed when low (40 mg) and high (240 mg) dosages of EGb were compared. This lack of difference between EGb dosages compared with the discrimination from placebo suggests that part of the treatment effect was a correction of a decrease of alpha activity occurring with placebo. This hypothesis was further explored in the study of Le Bars¹⁰, which demonstrated a spontaneous decrease of alpha activity during the day of the placebo session, possibly due to well known circadian changes of EEG, apparently absent during the EGb sessions. Further, the dose response to EGb was found to follow a bimodal curve. In accordance with previous studies reporting a dose–response relationship, alpha changes that occurred immediately within 3 h after EGb intake were dose dependent and could be correlated to a decrease of drowsiness, as assessed by a vigilance self-rating scale. However, the late EEG changes observed at 7 and 9 h post-dosing were not dose dependent or correlated to significant changes on the vigilance rating scale. This finding is in accordance with the Kunkel study outcomes measuring the EGb effect after 3 days of treatment. This apparent double mode of action of EGb in the CNS will require further work to determine its clinical relevance. Nevertheless, it could obscure the interpretation of outcomes when effects of acute single doses are compared with those obtained after chronic treatments.

Efficacy and safety in clinical studies

A review of the literature by Kleijnen and Knipschild summarized the findings obtained before 1992 with EGb in patient populations suffering from cognitive impairment¹⁶. The studies, mainly undertaken in Europe, used as an inclusion criterion diagnosis of ‘cerebral insufficiency’. This

Table 4 Electrophysiology in patient population with mild cognitive disorders

Publication (dosing regimen)	EEG changes	Outcome measure results
Hofferberth ¹² (80 mg tid, 12 weeks)	Decrease theta/alpha ratio	Statistically significant difference from placebo at 12 weeks
Rai <i>et al.</i> ¹³ (40 mg tid, 24 weeks)	Decrease slow activity	Statistically significant difference from placebo at 12 weeks
Gessner <i>et al.</i> ¹⁴ (40 mg tid, 12 weeks)	Decrease theta/alpha ratio	NS. Statistically significant difference from placebo only in subgroup with slow baseline background
Pidoux <i>et al.</i> ¹⁵ (30 mg bid, 12 weeks)	Decrease theta	Statistically significant difference from placebo at 12 weeks

has no equivalent in the current classification of disease (ICD-10 or DSM-IV), but includes signs and symptoms very similar to those integrated in the so-called 'age associated memory impairment' syndrome, as well as in incipient dementia and mood-affective disorders. Of the 40 trials reviewed, 20 were double-blind studies and only eight met the minimum criteria to be considered an adequate Randomized Clinical Trial (RCT). All the studies used 100–160 mg day⁻¹ EGb chronic doses and reported significant improvements of the clinical global impression after a minimum 6- to 12-week treatment. The responder rate varied from 20 to 70% depending on the study. Results obtained in such a non-specific diagnosis framework, however, may not necessarily apply to pure cognitive disorders and are difficult to integrate in a review of EGb efficacy.

Another review of the literature by Letzel selected exclusively EGb studies enrolling patient populations with a diagnosis of cognitive disorder¹⁷. Of 25 randomized, double-blind, placebo-controlled EGb studies available at that time, eight explicitly included demented patients and three applied standard inclusion criteria of dementia using DSM-III-R. Overall, 23 studies reported a statistically significant difference favourable to EGb on at least one of the three levels of assessment: clinical global impression, psychometric, or social behaviour and daily living. Of the 18 studies that included simultaneous assessments of the clinical global impression and the psychometric, 10 demonstrated that EGb effect could be discriminated from placebo at a statistical level of significance. When only dementia was considered as the population of interest, seven of the eight trials available reported a significant treatment effect. Five of these trials showed positive results

simultaneously in at least two levels of assessment (clinical global impression and psychometric). Regarding safety, no significant difference was found between EGb and placebo. In a study population of 739 patients, the most frequent events were gastrointestinal (19 patients, 2.6%), headache (7 patients, 0.9%), sleep disturbances and dizziness (3 patients, 0.4%) and skin eruptions (2 patients, 0.3%).

Since Letzel's review, the efficacy of EGb has been further supported by results obtained from a multi-centre RCT conducted in the United States, which enrolled 327 patients with Alzheimer's Disease (AD) or Multi-Infarct Dementia¹⁸. Whereas the largest study conducted in Europe used 240 mg day⁻¹ EGb during a 24 week period and focused on dementia of mild to moderate severity¹⁹, the North American study tested a dose of 120 mg day⁻¹ over 52 weeks and included patients with a broader range of impairment, as assessed by MMSE scores ranging from 9 to 26 and Global Deterioration Scale (GDS) scores of 3 to 6. At the 52-week endpoint, the group that received EGb did not show a significant worsening on the psychometric scale (cognitive subtest of the Alzheimer's Disease Assessment Scale or ADAS-Cog), whereas the placebo group showed a worsening of 1.5 points, resulting in a statistically significant difference favouring EGb (1.4 points, $P = 0.04$). On the Geriatric Evaluation by Relative's Rating Instrument scale, used by the caregivers to assess daily living and social behaviour, mild improvement was observed for the EGb group, whereas the placebo group worsened. The mean treatment effect of 0.14 points was statistically significant ($P = 0.004$). No difference was found on the clinical global impression scale.

To facilitate a historical comparison between EGb

Table 5 Comparison of three randomized controlled trials with EGb in dementia with mild to moderate impairment

Publication (dosing regimen)	Level of assessment	Outcome measure results
Hofferberth ¹² (21 AD patients on 240 mg EGb, 19 patients on placebo for 12 weeks)*	Complex reaction time	Favourable trend for EGb
	Memory and attention with timed test (SKT) Global impression, total score of the Sandoz Clinical Assessment	$P < 0.001$, 50% responder rate by 5 SKT points with EGb, 0% with placebo 76% responder rate
Kanowski <i>et al.</i> ¹⁹ (79 patients on 240 mg EGb, 77 patients on placebo for 24 weeks)	Memory and attention with timed test (SKT)	$P < 0.05$, 38% responder rate at 4 points with EGb vs. 18% with placebo
	Global impression (CGI)	$P < 0.05$, 32% responder rate with EGb versus 17% with placebo
	Social behaviour (NAB)	NS, 33% responder rate with EGb vs. 23% with placebo
Le Bars <i>et al.</i> ²⁰ (154 patients on 120 mg EGb, 155 patients on placebo: 26 weeks post hoc analysis)	2 out of 3 assessments	$P < 0.005$, 28% responder rate with EGb vs. 10% with placebo
	Memory, vigilance and complex performance (ADAS)	$P < 0.04$, 26% improvement 4 points with EGb vs. 17% with placebo
	Global impression (CGI) Social behaviour (GERRI)	NS $P < 0.01$, 30% responder rate with EGb vs. 25% with placebo

* AD, Alzheimer's Disease.

studies, a post hoc intent-to-treat analysis utilizing a 6-month endpoint was recently performed on the North American data set²⁰. A summary of the outcomes of this analysis is provided in Table 5, along with those from the trials of Hofferberth¹² and Kanowski¹⁹ since they may be considered the most representative of the European data. Comparison of the North American results with those reported in the German studies might suggest that an increased EGb dose would result in an increased treatment effect. After a similar treatment duration (i.e. 24 weeks), the group in the Kanowski study treated with 240 mg EGb showed a positive outcome on the CGI and there was a higher percentage of improved patients. In the EGb group, 38% of the patients reached the highest cut-off point on the cognitive scale vs. 27% in the North American study. Both showed a similar placebo response (18%). The increase of the responder rate, however, does not seem to be linear with the increase in dosage. That is, doses higher than 240 mg may not significantly improve the effects of treatment. This pattern of response was previously predicted by the EEG results of Le Bars¹⁰.

Ultimately, a control study with multiple doses of EGb will be needed to clarify the dose–response relationship and to help delineate the optimal regimen to obtain symptomatic improvement within at least a 6-month period. Future trials designed to assess changes in the course of the disease (i.e. preventative effect) would help delineate the role this special extract of *Ginkgo biloba* can play as an alternative to cholinesterase inhibitors or an adjunct agent for the treatment of dementia.

Overall, the efficacy of EGb has been demonstrated in cognitive disorders using neuropsychological assessments and electrophysiological tests. However, many trials have yielded discrepant findings, most likely due to differences in study population and trial design. To guarantee success in future research as well as in medical interventions, the population of interest should show an objective cognitive impairment at baseline, the outcome measures should include broad assessments of cognition (not exclusively memory tests) and treatment should explore doses higher than 240 mg day⁻¹ in order to detect a plateau of response to EGb.

References

- Warot D, Lacomblez L, Danjou P, Weiller E, Payan C, Puech AJ. Comparative effects of *Ginkgo biloba* extract on psychomotor performance and memory in healthy volunteers. (In French.) *Therapie* 1991; **46**: 33–6.
- Subhan Z, Hindmarch I. The psychopharmacological effects of *Ginkgo biloba* extract in normal healthy volunteers. *Int. J. Clin. Pharm. Res.* 1984; **IV** (2): 89–93.
- Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d'Arbigny P. Effect of two doses of *Ginkgo biloba* extract (EGb 761) on the dual-coding test in elderly subjects. *Clin. Ther.* 1993; **15**: 549–58.
- Grassel E. The influence of *Ginkgo biloba* extract on mental performance, a double-blind study under computerized measurement conditions in patients with cerebral insufficiency. (In German.) *Fortschr. Med.* 1992; **110**: 73–6.
- Hofferberth B. Effect of *Ginkgo biloba* extract on neurophysiological and psychometric findings in patients with cerebro-organic syndrome. (In German.) *Arzneim.-Forsch./Drug Res.* 1989; **39** (II): 918–22.
- Israel L, Dell'Accio E, Martin G, Hugonot R. *Ginkgo biloba* extract and memory training programs. Comparative assessment on elderly out-patients. (In French.) *Psychol. Med.* 1987; **19**: 1431–9.
- Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. *Hum. Psychopharm.* 1987; **2**: 159–69.
- Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U. Central nervous system effects of *Ginkgo biloba*, a plant extract. *Am. J. Ther.* 1996; **3**: 63–73.
- Kunkel H. EEG profile of three different extractions of *Ginkgo biloba*. *Neuropsychobiology* 1993; **27**: 40–5.
- Le Bars P, Itil TM, Salzman C, Saito A, Bucci P. QEEG for dose-finding of new psychotropics and antidementia drugs In: Kimura J, Shibasaki H, eds. *Recent Advances in Clinical Neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology*, 15–19 October 1995, Kyoto, Japan. Amsterdam: Elsevier, 1996: 780–3.
- Luthringer R, d'Arbigny P, Minot R, Toussaint M, Dago KT, Macher JP. EEG and EPs mapping profile of *Ginkgo biloba* extract (EGb 761). *Clin. Neuropharm.* 1992; **15** (Suppl. I): 152B.
- Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. *Hum. Psychopharmacol.* 1994; **9**: 215–22.
- Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of *Ginkgo biloba* extract ('Tanakan') in elderly out-patients with mild to moderate memory impairment. *Curr. Med. Res. Opinion* 1991; **12**: 350–5.
- Gessner B, Voelp A, Klasser M. Study of the long-term action of *Ginkgo biloba* extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. *Arzneim.-Forsch./Drug Res.* 1985; **35**: 1459–65.
- Pidoux B, Bastien C, Niddam S. Clinical and quantitative EEG double-blind study of *Ginkgo biloba* extract (GBE). *J. Cereb. Blood Flow Metab.* 1983; **3** (Suppl. I): S556–7.
- Kleijnen J, Knipschild P. *Ginkgo biloba* for cerebral insufficiency. *Br. J. Clin. Pharmacol.* 1992; **34**: 352–8.
- Letzel H, Haan J, Feil WB. Nootropics: Efficacy and tolerability of products from three active substance classes. *J. Drug Dev. Clin. Pract.* 1996; **8**: 77–94.
- Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of *Ginkgo biloba* for dementia. *JAMA* 1997; **278** (16): 1327–32.
- Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the *Ginkgo biloba* special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatry* 1996; **29**: 47–56.
- Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the *Ginkgo biloba* extract EGb 761 in dementia. *Dement. Geriatr. Cogn. Disord.* 2000; **11**: 230–7.